Iona Hohn
Head of Investor Relations
Replay available
Lineage Cell Therapeutics, Inc. (AMEX: LCTX) Q3 2025 earnings conference call, held 2025-11-06. Replay captured from the company's public earnings webcast.

Head of Investor Relations
Chief Executive Officer
Chief Financial Officer
Analyst, B. Riley Securities
Analyst, H.C. Wainwright
Analyst, Titan Partners
Analyst, Raymond James
Analyst
Welcome to the Lineage Cell Therapeutics 3rd Quarter 2025 Conference Call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investor section of Lineage's website at www.lineagesell.com. This call is subject to copyright and is the property of Lineage. And the recordings, reproductions, or transmissions of this call without the express written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Iona Hohn, Head of Investor Relations at Lineage. Ms. Hohn, please go ahead. Thank you, Angela. Good afternoon, and thank you for joining us. A press release reporting our third quarter 2025 financial results was issued earlier today, November 6, 2025, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements. which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements. For a discussion of certain factors that could cause the company's results or performance to differ, we refer you to the forward-looking statement sections in today's press release and in the company's SEC filings, including its most recent annual report on Form 10-K and in subsequent SEC filings. We caution you not to place undue reliance on any forward-looking statements, which speak only as of today and ...